Trial Information - Phase III
ORIENT-15: A Multicenter, Double-Blind, Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination with Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
Protocol ID: CIBI308A301
Sponsor: Innovent Biologics Ct.
Status: PENDING STAR
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
